Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04156126 · ClinicalTrials.gov registry record
Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 56
- Enrollment target
NCT04156126: Completed study, sponsored by Mayo Clinic.
NCT04156126 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04156126 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
Pregnancy is a unique period which requires alterations in the immune system to allow for tolerance of a haploidentical fetus. The goal of this study is to measure maternal blood levels of proteins known to promote immune tolerance in early implantation and pregnancy to look for associations between tolerance, miscarriage and failed embryo transfer. Establishing predictive factors of miscarriage and failed in vitro fertilization could have implications for a large portion of couples and serve to guide current and future family planning efforts.
Primary Outcome
Tolerance markers galectin-9, IL-4 and VEGF (-A,-B,-C,-D) will be measured for their concentration in maternal blood in women who conceived naturally, as determined by experimental standard curves.
Interventions
- OTHER Blood Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-08-23 |
| Est. Completion | 2024-06-01 |
What the finished NCT04156126 record still lists
NCT04156126 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Collection is the first listed.
NCT04156126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04156126 about?
NCT04156126 is a clinical study titled "Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer". Pregnancy is a unique period which requires alterations in the immune system to allow for tolerance of a haploidentical fetus. The goal of this study is to measure maternal blood levels of proteins known to promote immune tolerance in early implantation and pregnancy to look for associations between...
What is the current status of trial NCT04156126?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2019-08-23. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT04156126?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT04156126?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI